Prostate Cancer - Results from #40

REVIEW UroToday

Functional Imaging Guided Stereotactic Ablative Body Radiotherapy (SABR) with Focal Dose Escalation and Bladder Trigone Sparing for Intermediate and High-Risk Prostate Cancer: Study Protocol for Phase II Safo Trial - Beyond the Abstract July 1, 2024

The Impact of Prostate Volume Estimation on the Risk-Adapted Biopsy Decision Based on Prostate-Specific Antigen Density and Magnetic Resonance Imaging Score - Beyond the Abstract June 27, 2024

Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-Blind, Phase 3 Trial - Beyond the Abstract June 27, 2024

Patient Reported Sexual Adaptation Following Prostate Cancer Treatment: An Analysis of Related Variables and Sexual Outcomes Associated with Sexual Adaptation Styles - Beyond the Abstract June 25, 2024

The State of Intermediate Clinical Endpoints as Surrogates for Overall Survival in Prostate Cancer in 2024 - Beyond the Abstract June 24, 2024

PSMA-Positive Prostatic Volume Prediction with Deep Learning Based on T2-Weighted MRI - Beyond the Abstract June 24, 2024

Activity of Lutetium-177 Prostate-Specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study - Beyond the Abstract June 21, 2024

AZGP1 Deficiency Promotes Angiogenesis in Prostate Cancer - Beyond the Abstract June 20, 2024

Adequacy of Prostate Cancer Prevention and Screening Recommendations Provided by an Artificial Intelligence-powered Large Language Model - Beyond the Abstract June 18, 2024

TOward a comPrehensive Supportive Care Intervention for Older Men with Metastatic Prostate Cancer (TOPCOP3): A Pilot Randomized Controlled Trial and Process Evaluation - Beyond the Abstract June 18, 2024

A Systematic Review and Meta-analysis of the Impact of Local Therapies on Local Event Suppression in Metastatic Hormone-sensitive Prostate Cancer - Beyond the Abstract June 13, 2024

Magnetic Resonance Imaging-Based Prostate Cancer Screening in Carriers of Pathogenic Germline Mutations: Interim Results from the Initial Screening Round of the Prostate Cancer Genetic Risk Evaluation and Screening Study - Beyond the Abstract May 30, 2024

The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients - Beyond the Abstract May 23, 2024

Transperineal or Transrectal Magnetic Resonance Imaging-Targeted Biopsy for Prostate Cancer Detection - Beyond the Abstract May 20, 2024

Prediction of Plasma ctDNA Fraction and Prognostic Implications of Liquid Biopsy in Advanced Prostate Cancer - Beyond the Abstract May 17, 2024

A Comprehensive National Survey of Prostate-specific Antigen Testing and Prostate Cancer Management in France: Uncovering Regional and Temporal Disparities - Beyond the Abstract May 16, 2024

Diffuse Pneumonitis after Lutetium-177-PSMA-617 Treatment in a Patient with Metastatic Castration-Resistant Prostate Cancer - Beyond the Abstract May 9, 2024

Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation - Beyond the Abstract May 7, 2024

Loss of SYNCRIP Unleashes APOBEC-Driven Mutagenesis, Tumor Heterogeneity, and AR-Targeted Therapy Resistance in Prostate Cancer - Beyond the Abstract May 1, 2024

Ectopic JAK-STAT Activation Enables the Transition to a Stem-like and Multilineage State Conferring AR-Targeted Therapy Resistance - Beyond the Abstract May 1, 2024

Page 3 of 57